Biotinylated Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His,Avitag™

Customer Reviews
Cat. No. / Size
Price
Qty
GLE-V82E3-200ug
$1580.00
GLE-V82E3-1mg (200ug X 5)
$6080.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    Glycoprotein E/gE (VZV)

  • Source

    Biotinylated Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His,Avitag (GLE-V82E3) is expressed from human 293 cells (HEK293). It contains AA Ser 31 - Ala 546 (Accession # Q9J3M8-1).

    Predicted N-terminus: Ser 31

    Request for sequence
  • Molecular Characterization

    Glycoprotein E/gE (VZV) Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 61.9 kDa. The protein migrates as 60-65 kDa and 70-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    Glycoprotein E/gE (VZV) SDS-PAGE

    Biotinylated Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     Glycoprotein E/gE (VZV) ELISA

    Immobilized Biotinylated Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His,Avitag (Cat. No. GLE-V82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) with a linear range of 0.06-2 ng/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.

Recent Advances

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background